Fenwick Represents Veracyte in Pending Acquisition of HalioDx

Fenwick acted as U.S. counsel to Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, in its pending acquisition of HalioDx, an immuno-oncology diagnostics company based in Marseille, France, for approximately €260 million.

The acquisition will bring strategic benefits for Veracyte’s global growth by enabling IVD test development and manufacturing, deepening its scientific capabilities and expanding its cancer diagnostics scope to eight of the 10 top cancers in the U.S. More information can be obtained from Veracyte’s announcement.

The Fenwick transaction team included corporate partner Doug Cogen and associate Michael Shaw; technology transactions partner Jake Handy; executive compensation and employee benefits partner Elizabeth Gartland and associate Bryan Belok; privacy and cybersecurity partner Jim Koenig, director Brent Hoard and manager Sarah Borchers.

Latham & Watkins LLP acted as French counsel to Veracyte in the transaction.